Institutional investors and hedge funds own 10.01% of the company’s stock. Shares of LGVN opened at $1.55 on Tuesday. The stock’s 50-day moving average price is $1.60 and its 200 day moving ...

LGVN has made substantial progress with its signature treatment, Lomecel-B, in treating both HLHS and Alzheimer's Disease and we suggest investors take a look at this stock before more good news ...

Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on Longeveron (LGVN – Research Report ... Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.

Longeveron ( NASDAQ:LGVN ) Full Year 2024 Results Key Financial Results Revenue: US$2.39m (up 237% from FY 2023). Net... Wa'el Hashad Wa'el Hashad, Chief Executive Officer, Longeveron Inc. Pivotal ...

Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) ...